ORIGINAL ARTICLE

Descriptive Study of Sensitization to Methylchloroisothiazolinone and Methylisothiazolinone in a Skin Allergy Unit

B. de Unamuno,* V. Zaragoza Ninet, C. Sierra, J. de la Cuadra

Servicio de Dermatología, Hospital General Universitario de Valencia, Valencia, Spain

Received 24 October 2013; accepted 2 February 2014
Available online 30 September 2014

KEYWORDS
Methylisothiazolinone;
Methylchloroisothiazolinone;
Sensitization;
Allergic contact dermatitis;
Patch tests

Abstract
Background: Methylchloroisothiazolinone (MCI) and methylisothiazolinone (MI) are heterocyclic compounds used as preservatives in cosmetic and industrial products. They continue to be common allergens, causing positive patch test reactions in 2% to 4% of patients tested.

Material and methods: We searched the database at our skin allergy unit for all cases of sensitization to MCI/MI and MI diagnosed between January 1980 and March 2013.

Results: Patch tests were performed with MCI/MI in 8705 patients and with MI in 404 patients. In total, 222 patients (2.55%) were sensitized to MCI/MI and 21 (5.19%) were sensitized to MI. The incidence of MCI/MI cases peaked between 1998 and 2005 and again between 2009 and 2013. Of the 222 patients with MCI/MI sensitization, 142 were women (64%) and 49 were men (36%); the mean age was 43 years. The most frequently affected areas were the hands (54% of cases), the arms (36%), and the face (35%); 75.67% of cases were due to cosmetics and 2.25% were due to paint. Of the 21 patients with MI sensitization (mean age: 50 years), 12 were women (57%) and 9 were men (43%). The most common site of involvement in this group was the face (71% of cases), followed by the arms (38%) and the hands (29%). All the cases were due to cosmetics.

Conclusions: Our data show that sensitization to the combination of MCI and MI alone has increased in recent years. It would appear to be necessary to add MI to the baseline patch test series, although the test concentration has yet to be determined.

© 2013 Elsevier España, S.L.U. and AEDV. All rights reserved.

* Please cite this article as: de Unamuno B, Zaragoza Ninet V, Sierra C, de la Cuadra J. Estudio descriptivo de la sensibilización a metilcloroisotiazolinona/metilisotiazolinona en una unidad de alergia cutánea. Actas Dermosifiliogr. 2014;105:854-859.
* Corresponding author.
E-mail address: blancanamuno@yahoo.es (B. de Unamuno).

1578-2190/$ - see front matter © 2013 Elsevier España, S.L.U. and AEDV. All rights reserved.
INTRODUCTION

Isothiazolinones are heterocyclic compounds that are used as biocides because of their antimicrobial properties. The 6 known types of isothiazolinones are methylisothiazolinone (MI), methylchloroisothiazolinone (MCI), benzisothiazoline, octylisothiazolinone, dichloroacylhistiazolinone, and butylbenzoisothiazolinone. These compounds are used as preservatives in a large number of cosmetic products, such as moisturizing cream, gel, shampoo, face masks, makeup, and wet wipes. They can also be found in detergent, clothing conditioner, cleaning fluid, pesticide, water-based paint, lubricant, cutting oil, and air conditioning systems.

MCI/MI was authorized for use as a preservative in 1980. During the following decade, the frequency of allergic contact dermatitis to MCI/MI became epidemic, with sensitization rates higher than 5%. Consequently, in 1990, the maximum authorized concentration in cosmetic products was reduced to 7.5 ppm in leave-on products and 15 ppm in rinse-off products. Sensitization rates remain high, at around 2-4%.

MI is less effective as a biocide and, therefore, has to be used at higher concentrations than MCI. MI has been used in industrial products since the first decade of the century; since 2005, it can be used alone as a preservative in cosmetic products at 100 ppm. MI was initially thought to be a safer alternative, given that MCI was a significantly more potent allergen than MI. However, cases of sensitization to MI alone were subsequently reported. The first cases of sensitization to MI in industrial products were reported in 2004 and 2006; the first cases of allergic contact dermatitis to MI in cosmetic products were reported in 2010.

The currently used patch test (Kathon CG) contains a 3:1 mix comprising MCI (1.125%) and MI (0.375%), magnesium nitrate, magnesium chloride, and water. It was included in the standard series of the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC) in 1990. In our center, patch testing with MCI/MI at 100 ppm in water has been used since 1987, and MI alone at 500 ppm in water has been used since November 2011.

In the present study, based on all cases of sensitization to MCI/MI and MI diagnosed in the skin allergy unit of our dermatology department, we retrospectively analyze patient characteristics and the place, source, and relevance of the sensitization.

Material and Methods

We performed a search for all cases of sensitization to MCI/MI and MI diagnosed in the Skin Allergy Unit of the Dermatology Department of Hospital General Universitario de Valencia, Valencia, Spain. Information was retrieved from the database of all patients who underwent patch testing from January 1980 to March 2013. The variables recorded were as follows:

- Demographic details: age and sex
- Personal history: occupation and personal and/or family history of atopy
Table 1  MOAHLE Index.

<table>
<thead>
<tr>
<th></th>
<th>MCI/MI, Positive Result (n=222), No. (%)</th>
<th>MCI/MI, Negative Result (n=8483), No. (%)</th>
<th>MI, Positive Result (n=21), No. (%)</th>
<th>MI, Negative Result (n=383), No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>36 (49)</td>
<td>38 (3223)</td>
<td>43 (9)</td>
<td>32 (122)</td>
</tr>
<tr>
<td>Occupational dermatitis</td>
<td>5 (11)</td>
<td>9 (763)</td>
<td>5 (1)</td>
<td>11 (42)</td>
</tr>
<tr>
<td>Atopic dermatitis</td>
<td>22 (78)</td>
<td>20 (1696)</td>
<td>19 (4)</td>
<td>23 (88)</td>
</tr>
<tr>
<td>Dermatitis, hands</td>
<td>54 (119)</td>
<td>41 (3478)</td>
<td>29 (6)</td>
<td>41 (157)</td>
</tr>
<tr>
<td>Dermatitis, legs</td>
<td>18 (40)</td>
<td>11 (933)</td>
<td>14 (3)</td>
<td>8 (31)</td>
</tr>
<tr>
<td>Dermatitis, face</td>
<td>35 (77)</td>
<td>23 (1951)</td>
<td>71 (15)</td>
<td>30 (115)</td>
</tr>
<tr>
<td>Age &gt;40 y</td>
<td>58 (128)</td>
<td>65 (5514)</td>
<td>71 (15)</td>
<td>63 (241)</td>
</tr>
</tbody>
</table>

Abbreviations: MCI, methylchloroisothiazolinone; MI, methylisothiazolinone; MOAHLE, male, occupational dermatitis, atopic dermatitis, hand dermatitis, leg dermatitis, face dermatitis, age >40 years.

- Clinical data: location of the lesions, time since onset, and diagnosis before patch testing.
- Patch test: series tested (according to the individual diagnosis), concomitant allergens, place of exposure (workplace/home), source of sensitization, and relevance of positive results.
- Other diagnostic tests: blood tests (total immunoglobulin E, aeroallergens, T-cell populations), skin biopsy, photopatch, atopy prick test (prick test to the most common allergens [Dermatophagoides pteronyssinus, Olea europea, wild grasses, Parietaria judaica, Alternaria alternata, dog and cat dander, Platania acerifolia, Cupressus arizonica]), use test for rinse-off products, open application test for leave-on products.

Results

We performed patch tests with Kathon CG on 8705 patients and with MI on 404 patients between January 1980 and March 2013. We identified 222 patients who were sensitized to MCI/MI, that is, 2.55% of all patients tested. Women accounted for 64% of the population (143) and men 36% (79), with a mean age of 43 years and 31-50 years as the most frequently affected age group. A personal history of atopy was recorded in 22% and a family history in 25%. The data for the MOAHLE index are shown in Table 1. Incidence peaked between 1998 and 2005 and again between 2009 and 2013 (Fig. 1). Of note, the number of cases increased during the last 5 years (69 cases between January 2009 and March 2013), when the sensitization rate rose to 6.27%. Mean time from onset of the skin lesions to diagnosis by patch tests—32.67 months—was specified for 132 patients. Lesions were most frequently identified on the hands (54%), followed by the arms (36%), face (35%), neck (20%), legs (18%), eyelids (15%), axillae (9%), feet (9%), and upper part of the chest (5%). It is remarkable that more than 36% of patients had lesions at 3 or more sites and that these were classed as generalized in as many as 6%. In most patients (126), the initial diagnostic suspicion was allergic contact dermatitis; however, some patients were also initially diagnosed with other diseases such as dyshidrotic eczema (26), atopic dermatitis (22), endogenous eczema (24), irritant contact dermatitis (8), seborrheic dermatitis (4), psoriasis (4), photallergic contact dermatitis (3), phototoxic dermatitis (3), and protein contact dermatitis (1). Endogenous eczema was defined as nonexogenous eczema in which no markers of atopy were identified (personal or family history of atopy or allergic rhinitis, and visible flexural dermatitis).

The most frequently identified concomitant allergen was nickel, followed by fragrance mix and cobalt. In addition

Figure 1  Percentage of patients sensitized to MCI/MI by year: the first peak in incidence was between 1998 and 2005 and the second between 2009 and 2013.
to the standard series, the most common series used were preservatives (33%), cosmetics (4%), perfumes (12%), and the patient’s own products (2.22%). In the case of patients whose source of sensitization was paint, a cutting oil series (Marti Tor) was applied and revealed sensitization to benzylisothiazolinone and octylisothiazolinone. In some patients, the definitive diagnosis could only be made using additional tests, namely, atopy prick test and blood test for total IgE in patients with suspected atopic dermatitis and blood test for T-cell populations and skin biopsy in patients with a clinical picture suggestive of cutaneous T-cell lymphoma. In 163 patients (73%), the standard series was complemented by patch tests applied according to the individual suspected diagnosis.

A wide range of occupations were identified (68), the most common being homemaker and administrative staff. In most cases (95%), the patient did not become sensitized in the workplace; only 11 patients (5%) became sensitized at work (4 patients who worked with paint and 7 patients who handled cosmetic products [beauticians]).

The most frequent source of sensitization was cosmetic products (75.67%), mainly gel, shampoo, cream, moisturizing lotion, and wet wipes. The cause of sensitization was washing up liquid in 5.85% and paint in 2.25% (Table 2). No source of sensitization was specified in 40 patients.

After diagnosis was confirmed, all patients underwent periodic checkups to verify the relevance of the sensitization, which was classed as present in 86% of cases.

A total of 21 patients were sensitized to MI, that is, 5.19% of all those who underwent patch testing with MI alone. Of these 21 patients, 3 (14.28%) had negative results in the MCI/MI patch test. Twelve were women (57%) and 9 were men (43%), with a mean age of 50 years. The most frequently affected age group was 36 to 50 years. A personal and family history of atopy was only identified in 4 patients. Mean time from onset of the skin lesions to diagnosis was 6.7 months. Most lesions were on the face (71%), followed by the arms (38%), hands (29%), neck (24%), upper part of the chest (24%), eyelids (19%), axillas (19%), trunk (19%), legs (14%), and feet (5%). The lesions were classed as generalized in 19% of cases. As with MCI/MI, the initial suspected diagnosis in most patients (10) was allergic contact dermatitis. In addition to the standard series, the most common series used were preservatives (14%) and perfumes (10%). It is noteworthy that in the case of MI, the source of sensitization in all patients was cosmetic products; no cases were caused by paint. Only 1 case was caused in the workplace (beautician). Relevance was considered present in all patients.

Discussion

The rates of sensitization to MCI/MI we obtained are equivalent to those reported in the literature, that is, around 2-4%. Moreover, as in recent studies, we recorded a marked increase in the rate of sensitization to MCI/MI, which has risen to 6.27% in the last 5 years, although we did not record an increase in the rates of sensitization to other preservatives.

Uter et al. performed a retrospective study using the Information Network of Departments of Dermatology, which collects data from 56 dermatology departments in Germany, Switzerland, and Austria. The authors analyzed rates of sensitization to MCI/MI (0.01%) for the period 1992-2010, during which they found the prevalence to be 2.33%. In another retrospective study covering the period 2009-2011, the same authors recorded an increase in the prevalence of sensitization to MCI/MI of 2.3% in 2009 and 3.9% in 2011. They also observed an increase in sensitization to MI from 1.9% to 4.4%. In this second study, the authors state that the increase in sensitization to MCI/MI is probably due to cross-reactivity with MI. Lundov et al. recently observed an increase in the prevalence of sensitization to MCI/MI of 1% in 2010 to 2.4% in 2011-2012 and indicated that this increase is associated with a concomitant increase in sensitization to MI (from 2% in 2010 to 3.7% in 2012).

MI was named allergen of the year by the American Contact Dermatitis Society because of the increasing number of cases of primary sensitization. In 2005, MI alone was authorized for use as a preservative in cosmetics in order to reduce the high rate of sensitization to MCI/MI, since it was thought to be a poorly allergenic substance, although this led to increased rates of sensitization both to MCI/MI and to MI. Some authors suggest that sensitization to MI could be due to cross-reactivity between MCI and MI; nevertheless, more and more authors claim that MI is the primary allergen in most cases. Lundov et al. carried out a retrospective study and found the prevalence of sensitization to MI to be 1.5% between May 2006 and February 2010. Subsequent studies, such as that of Urwin and Wilkinson, who performed a retrospective analysis from 2008 to 2012, revealed greater sensitization rates, which reached 4.9% for MCI/MI and 4.6% for MI.

At our center, patch testing with MI at 500 ppm over 17 months revealed a sensitization rate of 5.19%. It is noteworthy that 14.28% of patients with a positive patch test result to MI were not detected with the MCI/MI patch at 100 ppm in water, indicating that MI could be an independent primary allergen. This percentage is lower than previously recorded (34-59%). The discrepancy could be attributed to the difference in the concentrations used in patch testing, which vary from study to study (200, 300, 500, 1000, and 2000 ppm). In Europe, most centers perform patch testing with MCI/MI at 100 ppm, that is, 0.5% of cases of sensitization to MI go undetected. García-Gavin et al. found that patch testing with MCI/MI at 100 ppm (containing MI at 25 ppm) was unable to detect sensitization to MI. Waton et al. carried out patch tests with MI at 200 and 500 ppm for

Table 2: Source of Sensitization.

<table>
<thead>
<tr>
<th>Source</th>
<th>MCI/MI</th>
<th>MI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gel</td>
<td>72</td>
<td>9</td>
</tr>
<tr>
<td>Shampoo</td>
<td>35</td>
<td>4</td>
</tr>
<tr>
<td>Cream/lotion</td>
<td>47</td>
<td>7</td>
</tr>
<tr>
<td>Wet wipes</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Washing up liquid</td>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>Paint</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Not specified</td>
<td>40</td>
<td>0</td>
</tr>
</tbody>
</table>

Abbreviations: MCI, methylchloroisothiazolinone; MI, methylisothiazolinone.
2 years and found 10 positive results with 500 ppm and only 5 positive results with 200 ppm; therefore, they suggested that the optimal concentration could be 500 ppm. However, the European Society of Contact Dermatitis recently recommended including a patch with MI at 2000 ppm.18

In the present study, sensitization to MCI/MI was more common in women (69%) aged 31 to 50 years. The most frequent site was the hands (54%), followed by the arms (36%) and face (35%). In the case of MI, mainly women aged 36 to 50 years were affected, and the most frequent site was the face (71%). Our data are consistent with those of Lundov et al.,19 who found a greater frequency of sensitization to MCI/MI and MI in women aged more than 40 years, with lesions on the hands and face. Similarly, McFadden et al.19 found higher rates of sensitization to MI in women aged 40 years, with lesions located on the face. The fact that the face is one of the most frequently involved sites could be explained in part by the fact that cosmetic products are the main source of sensitization. Therefore, most authors agree that the concentration of MI should be reduced in cosmetic products and make the distinction between rinse-off and leave-on products, suggesting that lower concentrations should be used in leave-on products.20

Most cases of occupational sensitization to MCI and MI reported in the literature involve painters. However, in our study, we only recorded 4 cases of sensitization associated with paint; all 4 were simultaneously sensitized to benzylisothiazolinone and octylisothiazolinone. Most of the cases we detected were in beauticians (7 patients), who handle cosmetic products at work.

It is noteworthy that in 6% of the patients we report, the lesions were considered generalized, with the result that additional tests had to be performed before patch testing in order to reach a definitive diagnosis. Therefore, we recommend performing patch tests in patients with generalized lesions in order to rule out possible allergic contact dermatitis to isothiazolinones.

MCI/MI is a common allergen in our setting. We found that the prevalence of sensitization to MCI/MI and MI has increased in recent years. Both previous studies and ours show that MI alone leads to primary sensitization and should be included in the standard series, although further studies are necessary to establish the optimal concentration. The face and hands are the most frequent locations of lesions in allergic contact dermatitis to isothiazolinones; however, patients can present lesions at various sites, and these can sometimes mimic other skin conditions.

Ethical Disclosures

Protection of persons and animals:
The authors declare that no experiments were performed on humans or animals for this investigation.

Confidentiality of data. The authors declare that they have followed their hospital’s protocol on the publication of data concerning patients and that all patients included in the study have received sufficient information and have given their written informed consent to participate in the study.

Right to privacy and informed consent. The author obtained informed consent from the patients and/or subjects referred to in this article. This document is held by the corresponding author.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We are grateful do David Baquedano for corrections to the manuscript and for his help with data management.

References

5. The Scientific Committee on Cosmetic Products and Non-Food Products Intended for Consumers. SCCFNP/0805/04. Opinion Concerning Methylisothiazolinone. COLIPA N. 9 P 94.
methylisothiazolinone in Finland—a multicentre study. Contact Dermatitis. 2011;64:49–53.